Rel-4,4,5,5-tetramethyl-2-((1R,2R)-2-methylcyclopropyl)-1,3,2-dioxaborolane

Catalog No. :
ACTNVE982
CAS No. :
1350713-20-0
Molecular Formula :
C10H19BO2
Molecular Weight :
182.07

IUPAC Name:4,4,5,5-tetramethyl-2-((1R,2R)-2-methylcyclopropyl)-1,3,2-dioxaborolane

Rel-4,4,5,5-tetramethyl-2-((1R,2R)-2-methylcyclopropyl)-1,3,2-dioxaborolane structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$461.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameRel-4,4,5,5-tetramethyl-2-((1R,2R)-2-methylcyclopropyl)-1,3,2-dioxaborolane
IUPAC Name4,4,5,5-tetramethyl-2-((1R,2R)-2-methylcyclopropyl)-1,3,2-dioxaborolane
MDL No.MFCD23704116
Molecular FormulaC10H19BO2
Molecular Weight182.07
SMILESC[C@H]1[C@H](B2OC(C)(C)C(C)(C)O2)C1
InChI KeyTUXCUWZCFQDMLZ-HTQZYQBOSA-N
Synonymtrans-2-Methyl-cyclopropyl Boronic Acid Pinacol Ester;Rac-4,4,5,5-tetramethyl-2-[(1r,2r)-2-methylcyclopropyl]-1,3,2-dioxaborolane, trans;1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[(1R,2R)-2-methylcyclopropyl]-, rel-;rel-4,4,5,5-Tetramethyl-2-[(1R,2R)-2-methylcyclopropyl]-1,3,2-dioxaborolane;rac-4,4,5,5-Tetramethyl-2-[(1R,2R)-2-methylcyclopropyl]-1,3,2-dioxaborolane
CAS No.1350713-20-0

Synthetic Route by SureRoute

1. ACTNVE982 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTNVE982 route product structure diagram
    ACTNVE9821350713-20-0
Inquiry

2. ACTNVE982 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTNVE982 route product structure diagram
    ACTNVE9821350713-20-0
Inquiry

Comments (0)